No resistant herpes simplex virus (HSV) observed in phase II trial with AIC316, AiCuris' novel herpes drug
HCMV DRUG Letermovir (AIC246) receives Fast Track from FDA. New data at 51st ICAAC
AiCuris’ novel HSV compound AIC316 shows efficacy in phase II
AiCuris receives Orphan Drug Designation for its innovative phase II drug AIC246 for the prevention of HCMV disease
AiCuris completes Phase II genital herpes trial with AIC316 ahead of time
AiCuris gained Bio.NRW research promotion
AiCuris Presents Preclinical and Phase 1 Data of its anti-HSV drug AIC316
AiCuris Announces AIC246 to be Successful in Treatment of Multiorgan HCMV Disease
The 50th ICAAC, Boston AiCuris presents Phase I Safety and PK Data of the novel anti-HCMV terminase inhibitor AIC246
AiCuris presents mechanism of action investigations of its novel anti-HCMV drug AIC246 at the International Herpesvirus Workshop
AiCuris’ novel resistance breaking HIV compound AIC292 in Phase I
Novel HCMV compound of AiCuris in phase IIb trial with bone marrow transplant recipients
AiCuris raises 55 Mio EUR (75 Mio USD)
AiCuris successfully completed phase I for novel herpes compound
AiCuris’ novel HCMV compound shows good tolerability and efficacy in phase II study
AiCuris to present phase II data for HCMV compound at ICAAC
If you have a media enquiry or further questions regarding public relation activities at AiCuris please contact:
Katja Woestenhemke
AiCuris Anti-infective Cures GmbH
Friedrich-Ebert-Str. 475
42117 Wuppertal
Phone: +49 (0)202 317 63 - 0
Fax: +49 (0)202 317 63 - 1177
E-Mail: press(at)aicuris.com